Mucosal corticosteroid therapy of IgA nephropathy.
The value of systemic immunosuppressive therapy for IgA nephropathy is uncertain. A recently completed randomized controlled phase II trial demonstrates that specially encapsulated budesonide, released preferentially in the terminal ileum, can reduce proteinuria and stabilize glomerular filtration rate in patients with IgA nephropathy.